Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

MagnifEye Production Contract with the UK’s Department of Health & Social Care

June 1, 2021

Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announces it has signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use Sensyne’s MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing programme.

The scope of this contract with DHSC is for a phased national roll-out over a three month period in care homes, GP practices and selected private sector organisations with large workforces.  Revenues will be shared with Excalibur Healthcare Services Limited under the terms of the exclusive agreement between the two companies. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: 

“This is a significant commercial milestone in Sensyne’s development and underline’s the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Dept of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic.”  
Press release

MagnifEye Production Contract with the UK’s Department of Health & Social Care

June 1, 2021

Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announces it has signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use Sensyne’s MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing programme.

The scope of this contract with DHSC is for a phased national roll-out over a three month period in care homes, GP practices and selected private sector organisations with large workforces.  Revenues will be shared with Excalibur Healthcare Services Limited under the terms of the exclusive agreement between the two companies. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: 

“This is a significant commercial milestone in Sensyne’s development and underline’s the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Dept of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic.”  
Press release

MagnifEye Production Contract with the UK’s Department of Health & Social Care

MagnifEye Production Contract with the UK’s Department of Health & Social Care

June 1, 2021

Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announces it has signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use Sensyne’s MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing programme.

The scope of this contract with DHSC is for a phased national roll-out over a three month period in care homes, GP practices and selected private sector organisations with large workforces.  Revenues will be shared with Excalibur Healthcare Services Limited under the terms of the exclusive agreement between the two companies. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: 

“This is a significant commercial milestone in Sensyne’s development and underline’s the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Dept of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic.”  
Press release

MagnifEye Production Contract with the UK’s Department of Health & Social Care

MagnifEye Production Contract with the UK’s Department of Health & Social Care

Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announces it has signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use Sensyne’s MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing programme.

The scope of this contract with DHSC is for a phased national roll-out over a three month period in care homes, GP practices and selected private sector organisations with large workforces.  Revenues will be shared with Excalibur Healthcare Services Limited under the terms of the exclusive agreement between the two companies. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: 

“This is a significant commercial milestone in Sensyne’s development and underline’s the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Dept of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic.”  
Arrange to meet us
Press release

MagnifEye Production Contract with the UK’s Department of Health & Social Care

June 1, 2021

Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announces it has signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use Sensyne’s MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing programme.

The scope of this contract with DHSC is for a phased national roll-out over a three month period in care homes, GP practices and selected private sector organisations with large workforces.  Revenues will be shared with Excalibur Healthcare Services Limited under the terms of the exclusive agreement between the two companies. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: 

“This is a significant commercial milestone in Sensyne’s development and underline’s the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Dept of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic.”